Question

A patient presents with thrombocytopenia, elevated bilirubin, rising creatinine, and elevated LDH. ADAMTS13 activity is 45%. What is the most appropriate next step in management?

• A. Plasmapheresis
• B. High-dose steroids
• C. Rituximab
• D. Eculizumab

Hint:

ADAMTS13 activity thresholds are critical for board exams:
$<$ 10% confirms TTP.
$>$ 10% (often normal) in the presence of MAHA and renal failure points to aHUS or secondary forms of TMA (like STEC-HUS or drug-induced).
Despite varying pathophysiology, empiric Plasma Exchange is never a wrong first reflex if TTP is even remotely suspected.

Answer 1

The Correct Option is A

Concept:
The patient presents with classic signs of a Thrombotic Microangiopathy (TMA).
Findings include microangiopathic hemolytic anemia (implied by elevated LDH and elevated unconjugated bilirubin), thrombocytopenia, and acute kidney injury (rising creatinine).
The defining differential branch point in TMA is the ADAMTS13 activity, which is reported here as 45%.
Explanation:
• Thrombotic Microangiopathies primarily encompass Thrombotic Thrombocytopenic Purpura (TTP) and Hemolytic Uremic Syndrome (HUS), including atypical HUS (aHUS).

• TTP is caused by a severe deficiency in the von Willebrand factor-cleaving protease, ADAMTS13.

• By consensus definition, TTP is diagnosed when ADAMTS13 activity is severely reduced, specifically $<$ 10%.

• In this patient, the ADAMTS13 activity is 45%, which effectively rules out classical TTP.

• With TTP ruled out, the triad of MAHA, thrombocytopenia, and prominent renal failure strongly points toward aHUS (complement-mediated TMA) or a secondary TMA.

• The definitive targeted therapy for aHUS is Eculizumab, a monoclonal antibody that inhibits the terminal complement cascade by binding to C5.

• However, the standard clinical approach is crucial here. In an acute presentation of a TMA, mortality is extraordinarily high without immediate intervention.

• Because ADAMTS13 test results typically take several days to return in most real-world clinical settings, the universal first-line empiric therapy for any suspected TMA is emergent therapeutic Plasma Exchange (Plasmapheresis or PEX).

• PEX removes potential autoantibodies and restores active ADAMTS13 (in the case of TTP) or removes mutated complement factors (in aHUS).

• Even though the premise of the question gives us the ADAMTS13 result upfront, algorithms often initiate PEX while ruling out secondary causes (like drugs, malignant hypertension, or Shiga toxin).

• Furthermore, per the provided answer key, Plasmapheresis is deemed the correct immediate next step, reinforcing its role as the critical early bridge therapy in undifferentiated or actively evolving TMA presentations before transitioning to highly specialized biologics like Eculizumab.

• High-dose steroids and Rituximab are used for immune-mediated TTP, which this patient does not have based on the ADAMTS13 levels.
Final answer:
Plasmapheresis is the most appropriate initial life-saving step in the management algorithm of acute TMA syndromes.